This inventor holds 14 USPTO granted patents and 1 published patent application. Top assignees: Praecis Pharmaceuticals, Inc., Provid Pharmaceuticals Inc., Sequenom, Inc.. Active years: 2003-2014.
Company Filing History:
9 out of 43 
4 out of 6 
1 out of 190 
Years Active: 2003-2014
Title: Innovations and Contributions of Charles Michael Cook
Introduction
Charles Michael Cook is a notable inventor based in Mendham, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of kinase inhibitors and related compounds. With a total of 14 patents to his name, Cook's work has had a profound impact on medical research and treatment options.
Latest Patents
Among his latest patents, Cook has developed compounds that serve as kinase inhibitors, which are crucial in the treatment of various diseases. One of his notable inventions focuses on inhibitors of antigen presentation by MHC class II molecules. This invention relates to pharmaceutical compositions containing these compounds and methods for their use. The compounds are particularly useful for treating or preventing diseases associated with T cell proliferation, such as autoimmune diseases and disorders.
Career Highlights
Throughout his career, Cook has worked with several prominent companies in the pharmaceutical industry. He has been associated with Praecis Pharmaceuticals, Inc. and Provid Pharmaceuticals Inc., where he has contributed to innovative research and development efforts. His expertise in the field has allowed him to make significant advancements in drug development.
Collaborations
Cook has collaborated with various professionals in the industry, including notable coworkers such as Christopher Self and Gary Olson. These collaborations have further enhanced his research and contributed to the success of his inventions.
Conclusion
Charles Michael Cook's contributions to the field of pharmaceuticals through his innovative patents and collaborations have made a lasting impact on medical science. His work continues to pave the way for advancements in the treatment of autoimmune diseases and other related disorders.